Colchicine for Community-Treated Patients with COVID-19 (COLCORONA): A Phase III, Randomised, Double-Blinded, Adaptive, Placebo-Controlled, Multicenter Trial

By
Justin.choi
-
0
151
Colchicine is an oral anti-inflammatory medication beneficial in gout, pericarditis, and coronary disease. Scientists investigated the effect of colchicine on the composite of COVID-19-related death or hospital admission.
[Lancet]
Tardif, J.-C., Bouabdallaoui, N., L’Allier, P. L., Gaudet, D., Shah, B., Pillinger, M. H., Lopez-Sendon, J., Luz, P. da, Verret, L., Audet, S., Dupuis, J., Denault, A., Pelletier, M., Tessier, P. A., Samson, S., Fortin, D., Tardif, J.-D., Busseuil, D., Goulet, E., … Boivin, G. (2021). Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. The Lancet Respiratory Medicine, 0(0). https://doi.org/10.1016/S2213-2600(21)00222-8 Cite
Abstract